|
|
 |
|
Viewing report
|
|
|
|
Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, Dec 2010, Pages: 50
Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Renal Cell Carcinoma (RCC) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global renal cell carcinoma therapeutics market. The report identifies the key trends shaping and driving the global renal cell carcinoma therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global renal cell carcinoma therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.
GlobalData estimates that the global renal cell carcinoma (RCC) market was valued at $1.3 billion in 2009 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 13.9% over the next eight years, to reach $3.8 billion by 2017. This high growth forecast is primarily attributed to population growth and high diagnosis rates. In addition, the RCC market will continue to be driven by the strong pipeline landscape of first-in-class drugs with better survival rates, safety and efficacy profiles.
Scope
The report provides information on the key drivers and challenges of the renal cell carcinoma therapeutics market. Its scope includes:
- Annualized renal cell carcinoma therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under different mechanisms of actions, which include hemopoietic growth factor, histone deacetylase (HDAC) inhibitors, hepatocyte growth factor/scatter factor (HGF/SF) antagonist, human anti-transforming growth factor, ribonucleotide reductase (RNR) inhibitor, kinesin spindle protein inhibitor, microtubule inhibitor, mitotic inhibitors, and monoclonal antibodies.
- Analysis of the current and future competition in the global renal cell carcinoma therapeutics market. Key market players covered are Pfizer Inc., Novartis AG, Wilex AG, Antigenics Inc., and Sanofi-Aventis
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the renal cell carcinoma therapeutics therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global renal cell carcinoma therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global renal cell carcinoma therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global renal cell carcinoma therapeutics market landscape? – Identify, understand and capitalize.
|
|
|
|
